IP Library › Granted Patent US 12,324,808
Granted Patent B2
US 12,324,808 · App. 18/084,033 · Granted Jun 10, 2025

Methods for the prevention and treatment of hearing loss

Inventors: Jian Zuo (Carlsbad, CA); Zhuo Li (Omaha, NE); Marisa Laura Zallocchi (Omaha, NE)
Assignee: Tiny Therapeutics, Inc
A61K31/5377A61F11/00A61K31/122A61K31/165A61K31/167A61K31/397A61K31/506A61K31/513A61K31/517A61K31/609A61K31/7036A61K33/243A61K45/06A61P27/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,324,808
App. No.
18/084,033
Granted
Jun 10, 2025
Kind
B2
Abstract

In one aspect, use of compounds as active agents to treat a hearing impairment and to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. Momelotinib and Fedratinib exhibit excellent protection against antibiotic-induced hearing loss in zebrafish and mice when administered prophylactically. In one aspect, Momelotinib or Fedratinib can be used as a therapy for the treatment and/or prevention of hearing loss. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims (3)

1. A method to protect ear hair cells from death caused by an antibiotic comprising:

administering to a mammal in need thereof an effective amount of a pharmaceutical composition containing a therapeutically active agent, wherein the therapeutically active agent is fedratinib or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the antibiotic is an aminoglycoside.

Assignments (6)
MERGER AND CHANGE OF NAME Recorded Oct 10, 2024
From: TING THERAPEUTICS LLC; TING THERAPEUTICS, INC.
To: TING THERAPEUTICS, INC
Reel/Frame 069164/0948 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2024
From: ZUO, JIAN
To: TING THERAPEUTICS LLC
Reel/Frame 068277/0994 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2024
From: LI, ZHUO
To: TING THERAPEUTICS LLC
Reel/Frame 068272/0340 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2023
From: CREIGHTON UNIVERSITY
To: TING THERAPEUTICS LLC
Reel/Frame 062447/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 28, 2022
From: ZALLOCHI, MARISA LAURA
To: TING THERAPEUTICS LLC
Reel/Frame 062222/0183 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2022
From: ZALLOCHI, MARISA LAURA
To: TING THERAPEUTICS, LLC
Reel/Frame 062156/0959 →
Continuity (3)
Continuation PCTUS2021041197 · Jul 10, 2021
Provisional Application 63050568 · Jul 10, 2020
Related Publication 20230285401A1 · Sep 14, 2023
References Cited (23)
US 8420595B2 · Kopke et al. · 2013 [cited by applicant]
US 9572815B2 · Zuo et al. · 2017 [cited by applicant]
US 20040110719A1 · Campbell · 2004 [cited by applicant]
US 20080280955A1 · McCamish · 2008 [cited by applicant]
US 20130085112A1 · Collard et al. · 2013 [cited by applicant]
US 20140235631A1 · Bunt et al. · 2014 [cited by applicant]
US 20160089371A1 · Liu et al. · 2016 [cited by applicant]
US 20170327557A1 · Chen · 2017 [cited by applicant]
US 20180161340A1 · Zuo et al. · 2018 [cited by applicant]
US 20200093923A1 · Zuo et al. · 2020 [cited by applicant]
WO 2016114655A1 · 2016 [cited by applicant]
WO 2018204764A1 · 2018 [cited by applicant]
WO WO2022020114A2 · 2022 [cited by examiner]
“Why use zebrafish to study human diseases?”, https://irp.nih.gov/blog/post/2016/08/why-use-zebrafish-to-study-human-diseases, published Aug. 9, 2016, accessed Feb. 6, 2025, attached as pdf (Year: 2016). [cited by examiner]
Atkinson et al. “hair Cell Regeneration after ATOH1 Gene Therapy in the Cochlea of Profoundly Deaf Adult Guinea Pigs,” PLoS ONE, Jul. 18, 2014 (Jul. 18, 2014), vol. 9, Iss. 7, pp. 1-11. entire document. [cited by applicant]
Dabestani et. al., Drug Repurposing of an EGF Inhibitor for Protection Against Noise-Induced Hearing Loss. 2020. Creighton University, M.Sc. Thesis. ProQuest, PQ No. 28001904; http://hld.handle.net/10504/127028. [cited by applicant]
Jarman et al. “The role of Atonal transcription factors in the development of mechanosensitive cells,” Seminars in Cell and Developmental Biology, May 1, 2013 (May 1, 2013), vol. 24, Iss. 5, pp. 438-447. entire document. [cited by applicant]
Kim, Harry. International Search Report of the ISA. PCT. Apr. 28, 2022. 1-3. [cited by applicant]
Kim, Harry. Written Opinion of the ISA. PCT. Apr. 28, 2022. 1-6. [cited by applicant]
Ng et al. Phase 1 dose-escalation study of momelotinib, a Janus Kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Inves… [cited by applicant]
Teitz et al., “CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss,” J. Exp. Med. Apr. 2, 2018, vol. 215, No. 4, pp. 1187-1203. [cited by applicant]
Emma J. Kenyon Identification of a series of hair-cell MET channel blockers thatprotect against aminoglycoside-induced ototoxicity. JCI Insight. 2021;6(7):e145704. https://doi.org/10.1172/jci.insight.145704. [cited by applicant]
Vijayakumar et al. In silico transcriptome screens identify epidermal growth factor receptor inhibitors as therapeutics for noise-induced hearing loss.Sci Adv. Jun. 21, 2024;10(25):eadk2299. doi: 10.1126/sciadv.adk2299. [cited by applicant]